PLAUR and neoplasm: Emerging research indicates that CAR-T cells can be engineered to specifically target SnCs, with targets such as FAP-alpha (Fibroblast Activation Protein-alpha) and uPAR (urokinase plasminogen activator receptor) showing potential to not only enhance the anti-tumor immune response but also mitigate the pro-tumorigenic effects of the SASP within the TME [15,48].